Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.
|Original language||English (US)|
|Journal||Diagnostic Microbiology and Infectious Disease|
|State||Accepted/In press - Jan 1 2018|
- Cystic fibrosis
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases